|
The investigation determined that a higher than expected valproic acid (valp) result was obtained from a vitros therapeutic drug monitoring (tdm) performance verifier processed using vitros chemistry products valp reagent lot 2511-33-2028 on a vitros xt 7600 integrated system.The investigation was unable to determine a definitive assignable cause.Based on historical qc results a vitros valp reagent lot 2511-33-2028 related issue is not a likely contributor to the event.Additionally, continual tracking and trending of complaints has not identified any signals that would point to a potential systemic issue with vitros valp reagent lot 2511-33-2028.As precision testing was not performed on the vitros xt 7600 system, an instrument related issue cannot be ruled out as a contributing factor of the event.However, there was no evidence suggesting that the vitros xt 7600 system malfunctioned.In addition, as no details of the customers initial protocol when preparing and handling the vitros tdm fluids was provided, an issue related to improper protocol cannot be completely ruled out as a contributing factor of the event.The customer reprocessed the same vials of vitros tdm fluids and obtained expected results.Therefore, an issue related the vitros tdm fluid is not a likely contributor of the event.However, prior to testing, the customer had recalibrated vitros valp lot 2511-33-2028 using a fresh reagent pack.Therefore, a suboptimal calibration from 26 may 2024 or a reagent pack related issue cannot be ruled out as contributors of the event.
|